Trastuzumab plus docetaxel is an approved anticancer regimen that is used worldwide for the treatment of HER2-overexpressing breast cancer notably in neoadjuvant setting (Coudert et al, 2007). This evidence concerns the gene ERBB2 and breast carcinoma.